| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:36 UTC |
|---|
| HMDB ID | HMDB0014420 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Olmesartan |
|---|
| Description | Olmesartan, also known as DE-092, belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond. In humans, olmesartan is involved in the olmesartan action pathway. Olmesartan is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on Olmesartan. |
|---|
| Structure | CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29) |
|---|
| Synonyms | | Value | Source |
|---|
| 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid | ChEBI | | 4-(Hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid | ChEBI | | 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate | Generator | | 4-(Hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate | Generator | | DE-092 | HMDB | | Olmesartan medoximil | HMDB | | Olmesartan medoxomil | HMDB | | Omesartan | HMDB | | 4-(Hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid | HMDB |
|
|---|
| Chemical Formula | C24H26N6O3 |
|---|
| Average Molecular Weight | 446.5016 |
|---|
| Monoisotopic Molecular Weight | 446.206638728 |
|---|
| IUPAC Name | 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid |
|---|
| Traditional Name | olmesartan |
|---|
| CAS Registry Number | 144689-63-4 |
|---|
| SMILES | CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O |
|---|
| InChI Identifier | InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29) |
|---|
| InChI Key | VTRAEEWXHOVJFV-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Biphenyls and derivatives |
|---|
| Direct Parent | Biphenyls and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Biphenyl
- Phenyltetrazole
- 1,2,4,5-tetrasubstituted imidazole
- Imidazole-4-carbonyl group
- N-substituted imidazole
- Azole
- Imidazole
- Heteroaromatic compound
- Tertiary alcohol
- Tetrazole
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Azacycle
- Organoheterocyclic compound
- Hydrocarbon derivative
- Alcohol
- Organic nitrogen compound
- Organic oxide
- Organic oxygen compound
- Organonitrogen compound
- Organooxygen compound
- Organopnictogen compound
- Aromatic alcohol
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 175 - 180 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.01 g/L | Not Available | | LogP | 5.9 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.59 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.4821 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.01 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 80.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2125.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 227.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 193.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 175.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 151.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 442.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 441.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 90.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1095.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 548.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1406.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 324.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 364.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 238.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 140.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 27.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Olmesartan,1TMS,isomer #1 | CCCC1=NC(C(C)(C)O)=C(C(=O)O[Si](C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=N[NH]2)C=C1 | 3708.6 | Semi standard non polar | 33892256 | | Olmesartan,1TMS,isomer #2 | CCCC1=NC(C(C)(C)O[Si](C)(C)C)=C(C(=O)O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=N[NH]2)C=C1 | 3746.7 | Semi standard non polar | 33892256 | | Olmesartan,1TMS,isomer #3 | CCCC1=NC(C(C)(C)O)=C(C(=O)O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C)C=C1 | 3862.6 | Semi standard non polar | 33892256 | | Olmesartan,2TMS,isomer #1 | CCCC1=NC(C(C)(C)O[Si](C)(C)C)=C(C(=O)O[Si](C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=N[NH]2)C=C1 | 3684.3 | Semi standard non polar | 33892256 | | Olmesartan,2TMS,isomer #2 | CCCC1=NC(C(C)(C)O)=C(C(=O)O[Si](C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C)C=C1 | 3824.4 | Semi standard non polar | 33892256 | | Olmesartan,2TMS,isomer #3 | CCCC1=NC(C(C)(C)O[Si](C)(C)C)=C(C(=O)O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C)C=C1 | 3838.4 | Semi standard non polar | 33892256 | | Olmesartan,3TMS,isomer #1 | CCCC1=NC(C(C)(C)O[Si](C)(C)C)=C(C(=O)O[Si](C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C)C=C1 | 3834.5 | Semi standard non polar | 33892256 | | Olmesartan,3TMS,isomer #1 | CCCC1=NC(C(C)(C)O[Si](C)(C)C)=C(C(=O)O[Si](C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C)C=C1 | 3701.8 | Standard non polar | 33892256 | | Olmesartan,3TMS,isomer #1 | CCCC1=NC(C(C)(C)O[Si](C)(C)C)=C(C(=O)O[Si](C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C)C=C1 | 4517.2 | Standard polar | 33892256 | | Olmesartan,1TBDMS,isomer #1 | CCCC1=NC(C(C)(C)O)=C(C(=O)O[Si](C)(C)C(C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=N[NH]2)C=C1 | 3912.1 | Semi standard non polar | 33892256 | | Olmesartan,1TBDMS,isomer #2 | CCCC1=NC(C(C)(C)O[Si](C)(C)C(C)(C)C)=C(C(=O)O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=N[NH]2)C=C1 | 3943.2 | Semi standard non polar | 33892256 | | Olmesartan,1TBDMS,isomer #3 | CCCC1=NC(C(C)(C)O)=C(C(=O)O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C(C)(C)C)C=C1 | 4041.1 | Semi standard non polar | 33892256 | | Olmesartan,2TBDMS,isomer #1 | CCCC1=NC(C(C)(C)O[Si](C)(C)C(C)(C)C)=C(C(=O)O[Si](C)(C)C(C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=N[NH]2)C=C1 | 4012.6 | Semi standard non polar | 33892256 | | Olmesartan,2TBDMS,isomer #2 | CCCC1=NC(C(C)(C)O)=C(C(=O)O[Si](C)(C)C(C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C(C)(C)C)C=C1 | 4154.1 | Semi standard non polar | 33892256 | | Olmesartan,2TBDMS,isomer #3 | CCCC1=NC(C(C)(C)O[Si](C)(C)C(C)(C)C)=C(C(=O)O)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C(C)(C)C)C=C1 | 4193.4 | Semi standard non polar | 33892256 | | Olmesartan,3TBDMS,isomer #1 | CCCC1=NC(C(C)(C)O[Si](C)(C)C(C)(C)C)=C(C(=O)O[Si](C)(C)C(C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C(C)(C)C)C=C1 | 4305.5 | Semi standard non polar | 33892256 | | Olmesartan,3TBDMS,isomer #1 | CCCC1=NC(C(C)(C)O[Si](C)(C)C(C)(C)C)=C(C(=O)O[Si](C)(C)C(C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C(C)(C)C)C=C1 | 4344.7 | Standard non polar | 33892256 | | Olmesartan,3TBDMS,isomer #1 | CCCC1=NC(C(C)(C)O[Si](C)(C)C(C)(C)C)=C(C(=O)O[Si](C)(C)C(C)(C)C)N1CC1=CC=C(C2=CC=CC=C2C2=NN=NN2[Si](C)(C)C(C)(C)C)C=C1 | 4588.4 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Olmesartan GC-MS (Non-derivatized) - 70eV, Positive | splash10-003i-3062900000-66da1fa4f726bf91355c | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Olmesartan GC-MS (2 TMS) - 70eV, Positive | splash10-004i-1000090000-53c6343e73cdd9538162 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Olmesartan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Olmesartan LC-ESI-qTof , Positive-QTOF | splash10-0a6r-0692700000-11f020dfbb889ac85e4e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olmesartan , positive-QTOF | splash10-0a6r-0692700000-11f020dfbb889ac85e4e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olmesartan 35V, Negative-QTOF | splash10-0uxs-0401900000-cd5b861ab18adf045ab0 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olmesartan 35V, Positive-QTOF | splash10-0a4i-0390100000-54b0de6532b2a6606a52 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 10V, Positive-QTOF | splash10-002b-0010900000-7248e647ec2c980aaf5f | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 20V, Positive-QTOF | splash10-000j-0173900000-939a2f46d78608eb934c | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 40V, Positive-QTOF | splash10-0079-6290000000-5391e796fbd1525a8962 | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 10V, Negative-QTOF | splash10-0udj-0113900000-aad428450b97d41a976f | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 20V, Negative-QTOF | splash10-0wml-0739700000-8723aec4a7e22bb975e6 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 40V, Negative-QTOF | splash10-0gbd-1911000000-8ea914bbddbfc4679a39 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 10V, Negative-QTOF | splash10-0f6t-0003900000-057ec33d13d54df0c4be | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 20V, Negative-QTOF | splash10-0fsm-1109100000-cd20e1af64ab97cbd41b | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 40V, Negative-QTOF | splash10-014i-2930000000-8334f854463cea004b20 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 10V, Positive-QTOF | splash10-0002-0010900000-8fdf38f12572465f1761 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 20V, Positive-QTOF | splash10-0550-0293200000-05222f637eae756fc82d | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olmesartan 40V, Positive-QTOF | splash10-000i-0590000000-56c8def2e6618cb2cf2c | 2021-09-25 | Wishart Lab | View Spectrum |
|
|---|